Fabrizio Citarella

14PUBLICATIONS
109CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 04, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study.

|Apr 07, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Feb 26, 2026
Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer.

Matteo Canale, Fabrizia Suzzi, Alberto Verlicchi

|Aug 19, 2025
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.

Amin H Nassar, Chul Kim, Tolulope Adeyelu

|Jul 12, 2025
TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis.

Leonardo Brunetti, Valentina Santo, Alessandro Galletti

|Aug 06, 2024
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.

Alessio Cortellini, Fabrizio Citarella, Alessia Vendittelli

Pageof 3

Frequent Collaborators

5 joint publications

Alessio Cortellini

2 joint publications

Alessandro Galletti

2 joint publications

David J Pinato

2 joint publications

Raffaele Giusti